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Background. Schistosomiasis elicits cross-regulatory immune responses, but it is unclear how antihelminthic treat-
ment affects this balance. This study integrates data on 13 cytokines elicited by 3 schistosome to examine how prazi-
quantel treatment alters immune polarization and whether post-treatment cytokine proﬁles inﬂuence reinfection status.
Methods. Venous blood from 72 Schistosoma haematobium–exposed participants was cultured with schistosome
egg, adult worm, and cercaria antigens pre– and 6 weeks post–praziquantel treatment. Innate inﬂammatory (tumor
necrosis factor α [TNF-α], interleukin(IL-)-6, IL-8), Th1 (interferon γ [IFN-γ], IL-2, IL-12p70), Th2 (IL-4, IL-5,
IL-13), Th17 (IL-17A, IL-21, IL-23p19), and regulatory (IL-10) cytokines were quantiﬁed via enzyme-linked immu-
nosorbent assay. Cytokine data was integrated using nonmetric multidimensional scaling and factor analysis.
Results. Egg-speciﬁc cytokine phenotypes became more proinﬂammatory post-treatment due to increased TNF-
α, IL-6, IL-8, IFN-γ, IL-12p70, and IL-23 levels. Post-treatment cercariae-speciﬁc responses were also more proin-
ﬂammatory reﬂecting elevated IL-8. In contrast, post-treatment adult worm-speciﬁc responses were less inﬂammato-
ry, reﬂecting lower post-treatment IL-6. A combination of egg-induced IL-6, IL-12p70, IL-21, and IL-23 and adult
worm-induced IL-5 and IL-21 post-treatment was associated with reduced reinfection risk 18 months later.
Conclusions. Praziquantel treatment markedly alters polarization of schistosome-speciﬁc cytokine responses,
and these changes, particularly in response to egg-stage parasites, may promote resistance to reinfection.
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Urogenital schistosomiasis is a debilitating disease caused
by the parasitic trematode Schistosoma haematobium,
which currently infects >100 million people [1]. Humans
are exposed to infective larvae (cercariae), which invade
via percutaneous penetration; adult male and female
worms, which mate in the urogenital tract; and eggs,
which are transmitted to the environment in urine. Re-
peated passage of eggs across the bladder and urogenital
tract leads to characteristic immune-mediated mor-
bidities [2, 3]. The World Health Organization advo-
cates schistosomiasis control via treatment with the
antihelminthic drug praziquantel (PZQ) [4] due to its
efﬁcacy at clearing infection [5, 6] and reducing the
prevalence of schistosome-associated morbidities [7].
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Praziquantel treatment also alters schistosome-speciﬁc
immune responses, and removal of infection and/or exposure
to antigens released from parasites damaged by treatment may
inﬂuence responses to subsequent infection [8–10]. Studies
showing a decline in the proportion of circulating T regulatory
(Treg) cells [11] and increased effector responses to parasite
[12, 13] and nonparasite antigens [14, 15] post-treatment indi-
cate that immunoregulatory mechanisms established during
infection are alleviated when infection is removed. Further-
more, PZQ-induced changes in antibody levels, CD23+ B cells
[16], and cellular proliferation [13] have been associated with
reduced Schistosoma mansoni reinfection rates, suggesting that
treatment may have longer-term beneﬁts in addition to tran-
sient infection clearance.
Taken together, these observations suggest that treatment
alters not only the magnitude of the host immune response
but also the phenotype of schistosome-speciﬁc responses.
However, although previous human studies have inferred rela-
tive changes in the phenotype of the schistosome-speciﬁc cy-
tokine response from changes in individual responses [12, 17],
this hypothesis has not been directly assessed. Importantly,
experimental models of helminth infection suggest that innate
cells and CD4+ T helper (Th) cells (Th1, Th2, Treg, and
Th17) cross-regulate one another during infection [18, 19],
and the interaction between these responses rather than levels
of individual cytokines alone may inﬂuence resistance to rein-
fection [20]. No studies to date have investigated schistosome-
speciﬁc, Th17-associated cytokine responses in humans
despite the role of Th17 in schistosome egg-mediated
immunopathologies in mice [21–23] and detectable levels of
Th17-type cytokines in plasma samples from S. haematobium–
exposed humans [24].
This study addresses 4 key hypotheses relating to the effect
of PZQ on schistosome-speciﬁc immune responses: (1) treat-
ment inﬂuences levels of schistosome-speciﬁc, Th17-associat-
ed cytokines in addition to the previously assayed cytokines;
(2) the cytokine environment (comprising markers associated
with innate inﬂammatory, Th1, Th2, Th17, and regulatory
responses) of treated individuals is fundamentally altered
relative to pretreatment responses; (3) the effects of treatment
on schistosome-speciﬁc cytokines differ between responses to
cercariae, adult worms and eggs; and (4) cytokine responses
elicited 6 weeks post-treatment inﬂuence reinfection rates.
Our results yield insights into the immunological effects of
antihelminthic treatment and how these relate to parasite life
history and the development of protective immunity.
MATERIALS AND METHODS
Ethical Permissions
Ethical approval was granted by the Medical Research Council
of Zimbabwe and the University of Zimbabwe’s Institutional
Review Board. Local permission was granted by the Provincial
Medical Director. Community members were informed of the
study aims and procedures in their local language (Shona),
and compliant participants provided written consent or assent
from a parent/guardian if aged <18 years.
Study Design
Participants were recruited from Murehwa District an S. hae-
matobium endemic region of Zimbabwe, which is part of
ongoing immunoepidemiological studies [14, 25–27]. Recruit-
ment was school-based, and non–school going community
members were invited to attend via community meetings.
After pretreatment sampling for parasitology and cytokine
assays, participants were treated with a single dose of PZQ
(40 mg/kg body weight). Blood samples for follow-up cytokine
assays were collected 6 weeks post-treatment, and parasitologi-
cal samples were collected 6 weeks, 6 months, and 18 months
post-treatment. To be included in the study, participants
had to meet the following 6 criteria: (1) life-long residents of
the area; (2) provided at least 2 urine and 2 stool samples on
consecutive days for parasitological analysis pretreatment and
6 weeks and 18 months post-treatment; (3) negative for
S. mansoni, soil-transmitted helminths, malaria, and human
immunodeﬁciency virus (HIV) at all 3 time points; (4) not
previously treated with antihelminthic drugs; (5) received
PZQ treatment after baseline sampling and cured of S. haema-
tobium infection (ie, no eggs detectable) 6 weeks post-treat-
ment; and (6) provided sufﬁcient blood for cultures and all
cytokine assays before treatment and 6 weeks post-treatment.
No cases were excluded for parasite coinfection; 6 HIV-posi-
tive cases were excluded, 7 participants refused treatment, and
23 participants provided insufﬁcient sample volume. In accor-
dance with the Medical Research Council of Zimbabwe ethical
guidelines on blood volumes that can be collected from young
children, children aged <5 years were excluded. Based on
these criteria, a total of 72 people were included in this longi-
tudinal study. High community-wide infection levels preclud-
ed inclusion of an untreated control group.
Parasitology and Virology
Schistosoma haematobium, S. mansoni, and soil-transmitted
helminth eggs were quantiﬁed via microscopic analysis of
urine and stool samples using standard urine ﬁltration and
Kato–Katz protocols respectively [28, 29]. A minimum of 2
samples per participant collected on consecutive days and 2
slides per stool sample were analyzed to quantify mean infec-
tion intensity before treatment and 6 weeks and 18 months
post-treatment. Some participants also provided parasitologi-
cal samples 6 months post-treatment, and these were used to
conﬁrm reinfection status. Plasmodium spp. were identiﬁed
via microscopic examination of blood smears and conﬁrmed
with a Paracheck rapid test (Orchid Biomedical Systems). HIV
160 • JID 2013:208 (1 July) • Bourke et al
was detected using DoubleCheckGold HIV1&2 Whole Blood
test (Orgenics), and positive cases were conﬁrmed using
Determine HIV1/2 Ag/Ab Combo (InvernessMedical).
Schistosome Antigens
Schistosoma haematobium cercariae antigen preparation
(CAP), whole adult worm homogenate (WWH), and soluble
egg antigen (SEA) were obtained from the Theodor Bilharz
Institute, Giza, Egypt. Antigens were conﬁrmed endotoxin-
free using previously described protocols [30] (Supplementary
Figure 1).
Whole Blood Culture
Venous blood samples were collected by trained nurses,
diluted 1:3 in culture medium (Roswell Park Memorial Insti-
tute medium supplemented with 2 mM L-glutamine and 100
U penicillin/streptomycin; all Lonza), and cultured in dupli-
cate wells coated with 10 µg/mL CAP, WWH, and SEA for 48
hours at 37°C in Anaerogen Compact anaerobic atmosphere
generation pouches (OXOID). Unstimulated cultures
(antigen-free media) were conducted in parallel. Fewer CAP
stimulations were conducted (n = 21) due to sample limita-
tions. Cell-free culture supernatants were frozen and assayed
within 12 months.
Cytokine Enzyme-Linked Immunosorbent Assay
Interferon γ (IFN-γ), tumor necrosis factor α (TNF-α), inter-
leukin 2 (IL-2,) interleukin 4 (IL-4), interleukin 5 (IL-5), in-
terleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10),
interleukin 12p70 (IL-12p70), interleukin 13 (IL-13), and
interleukin 21 (IL-21) (BD Biosciences) and interleukin 17A
(IL-17A) and interleukin 23p19 (IL-23p19) (eBiosciences)
were assayed in culture supernatants via enzyme-linked immu-
nosorbent assay. Ninety-six well plates were coated with 1 µg/
mL or 2 µg/mL (TNF-α and IL-23 only) capture antibody in
serum-free phosphate-buffered saline. Plates were washed 3
times and blocked for 2 hours with phosphate-buffered saline/
2% bovine serum albumin (Alpha Diagnostic International).
Recombinant cytokine standard dilutions were prepared from
starting concentrations of 1 ng/mL (IL-17A), 2 ng/mL (IL-
23p19 and IL-4),
5 ng/mL (IFN-γ, TNF-α, IL-5, IL-6, IL-8, and IL-10), 10 ng/mL
(IL-13), 20 ng/mL (IL-2 and IL-12p70), and 40 ng/mL (IL-
21). Supernatant samples were added to duplicate wells and
incubated overnight at 4°C.
After 3 washes, 0.5 µg/mL (IFN-γ, TNF-α, IL-2, IL-5, IL-6,
IL-8, IL-12p70, and IL-23) or 1 µg/mL (IL-4, IL-10, IL-13, IL-
17A, and IL-21) biotinylated detection antibody was added for
2 hour at 37°C. After 4 washes, 1:6000 streptavidin–horserad-
ish peroxidase (GE Healthcare) was added for 2 hour at 37°C.
Plates were washed 4 times and incubated with 3,3′,5,5′-
tetramethylbenzidine (TMB)-based streptavidin–horseradish
peroxidase substrate solution (Sigma-Aldrich). Assays were de-
veloped for 1.5 minutes (IL-8 only) or 5 minutes, stopped
with 25% hydrochloric acid, and read at 450 nm using Soft-
maxPro spectrophotometer software (Molecular Devices).
Statistical Analysis
Before analysis, mean cytokine concentrations in unstimulated
wells were subtracted from those of the corresponding antigen-
stimulated cultures for each participant to give antigen-speciﬁc
cytokine levels.
Cytokine responses to CAP, WWH, and SEA pretreatment
and 6 weeks post-treatment were square-root(x + 1) trans-
formed to meet parametric assumptions and compared using
repeated measures analysis of variance conducted using IBM
SPSS Statistics v.19 software. Pair-wise comparisons were made
using Fisher’s least signiﬁcant difference test [31]. Because
multiple comparisons may give rise to false positive results,
P values from analysis of variance were adjusted using the se-
quential Bonferroni method [32]. Raw P values are reported,
and those signiﬁcant postcorrection are considered highly
signiﬁcant.
In addition to 1-way analysis of cytokine levels, a data
reduction method—multidimensional scaling—was used to
visualize the multiple cytokine responses of each participant
in a 2-dimensional space. The nonparametric version of this
approach, nonmetric multidimensional scaling (NMS) [33],
was used because combined data did not meet parametric as-
sumptions. This approach was used to account for multicoli-
nearity and multiplicity between the 13 cytokines and to
identify how patterns of cytokine responses (an indicator of
cellular immune phenotype) were affected by treatment. A
single score was ﬁrst assigned to each participant correspond-
ing to their combination of CAP-, WWH-, or SEA-speciﬁc cy-
tokine responses ranked relative to all other participants
before treatment and 6 weeks post-treatment. Scores were then
plotted via NMS ordination to give a visual representation of
relative similarity and/or dissimilarity in participant cytokine
responses [33]. Hypothesis testing comparing pretreatment
and post-treatment NMS scores was conducted using the non-
parametric multiple response permutation procedure (MRPP)
[33]. Pearson’s correlation between the original cytokine levels
and NMS scores identiﬁed responses that varied most between
participants. Nonmetric multidimensional scaling and MRPP
were implemented using PC-ORD software as described in the
Supplementary information.
Factor analysis was used to reduce all square-root(x + 1)–
transformed, 6 week post-treatment SEA- and WWH-speciﬁc
cytokine responses into a smaller number of variables (princi-
pal components [PCs]) reﬂecting cytokine proﬁles [31]. Only
PCs that accounted for a greater than average proportion of
variance in the original cytokine data (eigenvalue > 1) and cor-
related with at least 2 of the original cytokine variables with
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factor loadings ≥0.5 or ≤−0.5 were included in subsequent
analyses [31]. Binary logistic regression was conducted with
sex, age, pretreatment infection intensity, and all SEA- and
WWH-speciﬁc cytokine proﬁles (6 week post-treatment PCs)
included simultaneously in the model as predictors of reinfec-
tion status (reinfected: ≥1 S. haematobium egg detected
between 6 and 18 months post-treatment; uninfected: no
S. haematobium eggs detected in post-treatment samples). The
Log likelihood ratio test statistic (D) and associated P value
were calculated for each predictor from the difference between
the Log likelihood model ﬁt for the full model to that where
the predictor was not included.
RESULTS
Cohort Characteristics Pretreatment
Pretreatment prevalence of S. haematobium infection within the
cohort was 58.3% with a mean infection intensity of 30.3 eggs/
10 mL urine (standard error of the mean [SEM], 9.82; range,
0–481 eggs/10 mL urine). Participants had a mean age of 9.3
years (SEM, 0.31; range: 5–17 years); 40 were males, and 32
were females. Demographic and infection characteristics of the
cohort are representative of the whole community [14].
Cercariae-, Adult Worm–, and Egg-Speciﬁc Cytokine
Responses Change Post-Treatment
Mean cytokine concentrations showed distinct post-treatment
dynamics according to antigen stimulation (Figure 1 and
Table 1). Concentrations of all SEA-speciﬁc responses, with
the exception of IL-5, were higher than pretreatment levels,
and this increase was statistically signiﬁcant for innate inﬂam-
matory (TNF-α, IL-6, and IL-8), Th1 (IFN-γ, IL-2, and IL-
12p70), and Th17 (IL-21 and IL-23p19) cytokines. Cercariae
antigen preparation –speciﬁc IL-8, IL-10, and IL-13 responses
were signiﬁcantly higher 6 weeks post-treatment, but CAP-
speciﬁc IL-23p19 levels were signiﬁcantly lower 6 weeks post-
treatment. Whole adult worm homogenate –speciﬁc TNF-α and
IL-6 were signiﬁcantly lower post-treatment than pretreatment.
Interleukin 5 responses to all antigens were lower post-treatment
than pretreatment, although this trend was not statistically sig-
niﬁcant. IL-21 responses to all schistosome antigens were higher
post-treatment than pretreatment, but only signiﬁcantly so for
SEA and WWH. Changes in SEA-speciﬁc TNF-α, IL-6, IL-8,
IFN-γ, IL-12p70, IL-21, and IL-23p19 and CAP-speciﬁc IL-8
were highly signiﬁcant (ie, remained signiﬁcant after Bonferroni
correction).
Consistent with systemic effects of treatment, levels of spon-
taneously produced IL-12p70 and IL-21 increased and IL-2,
IL-5, and IL-8 responses decreased in unstimulated cultures
post-treatment (Supplementary Figure 2).
Treatment Alters Polarization of Schistosome-Speciﬁc
Cytokine Proﬁles
Having identiﬁed differences between the levels of individual
cytokines following treatment, the implication of these
changes for polarization of whole blood cytokine responses
was investigated via NMS. Participant scores are plotted
according to similarity and/or dissimilarity between cytokine
proﬁles pre- and post-treatment (Figure 2). The individual
cytokines that varied most between participants are indicated on
spatial axes (correlation coefﬁcients in Supplementary Table 1).
Pre- and post-treatment responses to CAP varied predomi-
nantly according to IL-6 (axis 1) and IL-8 (axis 2). Distinct
groupings along axis 2 (Figure 2A) reﬂect the signiﬁcant diffe-
rence between pre- and post-treatment cytokine polarization
(T, −17.25; P < .001; A, 0.199) and particularly the highly signiﬁ-
cant increase in cercariae-speciﬁc IL-8 post-treatment (Table 1).
Variation between pre- and post-treatment WWH-speciﬁc
cytokine responses (Figure 2B) was mainly due to IL-6 (axis
1), reﬂecting the post-treatment decline in WWH-speciﬁc
innate inﬂammatory cytokines (Figure 1). No cytokines were
strongly associated with axis 2, and there was considerable
overlap between pre- and post-treatment responses, suggesting
that pre- and post-treatment cytokine proﬁles were similar,
consistent with the weakly signiﬁcant differences in individual
WWH-speciﬁc cytokines (Table 1). Although MRPP indicated
that WWH-speciﬁc post-treatment cytokine proﬁles changed
relative to baseline (T, −9.37; P < .001), the effect size of the
difference was small (A, 0.029).
Soluble egg antigen–speciﬁc cytokine responses exhibited a
clear shift post-treatment (Figure 2C) according to a combina-
tion of TNF-α, IL-6, IFN-γ, IL-12p70, and IL-23p19 (axis 1)
and TNF-α, IL-6, IL-8, IL-12p70, and IL-23p19 (axis 2) and
signiﬁcantly differed relative to pretreatment responses (T,
−72.67; P < .001; A, 0.391). The distinct clustering and low
overlap of pre- and post-treatment SEA-speciﬁc cytokine
responses indicate that this post-treatment shift was evident in
nearly all participants. The loading of IL-8 onto axis 2 but not
axis 1 and IFN-γ onto axis 1 but not axis 2 indicates that
participants differed in their IL-8 and IFN-γ responses in
addition to the more uniform upregulation of other proin-
ﬂammatory cytokines.
Spontaneous cytokine production was also affected by treat-
ment predominantly due to variation in IL-6 and IL-8 (axis 1)
and IL-21 (axis 2) after treatment relative to baseline
(Figure 2D). Pre- and post-treatment cytokine responses in un-
stimulated cultures differed signiﬁcantly (T, −2.804; P = .02),
although the effect size of this difference was low (A, 0.008).
Cytokine Proﬁles 6 Weeks Post-Treatment Predict Reinfection
Status
Of the study participants, 18 were reinfected within 18
months of treatment. Table 2 summarizes the characteristics
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Figure 1. Levels of innate inﬂammatory (A), Th1 (B), Th2 (C ), Th17 (D), and regulatory (E ) cytokines elicited by Schistosoma haematobium antigens
changed 6 weeks after curative praziquantel treatment. Cytokine responses were assayed in supernatants from 48 hours whole blood cultures stimulated
with S. haematobium cercariae (CAP), adult worm (WWH), and egg (SEA) antigens by enzyme-linked immunosorbent assay (CAP, n = 21; WWH, SEA,
and unstimulated, n = 72). Mean pretreatment concentrations (ng/mL) are represented by gray circles and post-treatment cytokine responses are repre-
sented by black circles. Levels of cytokine present in parallel unstimulated cultures were subtracted from those present in antigen-stimulated cultures
for each participant to account for levels of spontaneously produced cytokine. Pretreatment and 6 week post-treatment responses were compared for
each antigen by repeated measures analysis of variance. Horizontal bars indicate median values. IFN-γ, interferon γ; IL-2, interleukin 2; IL-4, interleukin
4; IL-5, interleukin 5; IL-6, interleukin 6; IL-8, interleukin 8; IL-10, interleukin 10; IL-12p70; interleukin 12p70; IL-13, interleukin 13; IL-17A, interleukin
17A; IL-21, interleukin 21; IL-23, interleukin 23; TNF-α, tumor necrosis factor α. *P < .05, **P < .01, ***P < .001.
PZQ and Schistosome-Speciﬁc Cytokines • JID 2013:208 (1 July) • 163
of the reinfected participants relative to those that remained
uninfected. Having identiﬁed reinfection within the cohort, we
sought to investigate whether the risk of reinfection
was related to the cytokine proﬁles mounted in response to
S. haematobium adult worm and egg antigens 6 weeks post-
treatment.
Factor analysis identiﬁed 4 proﬁles of 6 weeks post-
treatment cytokine responses to WWH and SEA (Table 3).
Principle component 1, which accounted for the most varia-
tion between cytokine proﬁles (15.6%), reﬂects regulatory and
Th2-polarized cytokine responses due to its positive loading
with SEA- and WWH-speciﬁc IL-10 and IL-13 and negative
loading with SEA-speciﬁc TNF-α, IL-6 and IL-23. Principle
component 2 reﬂects a combination of SEA-speciﬁc proin-
ﬂammatory and WWH-speciﬁc Th2- and Th17-polarized
responses. Principle component 3 reﬂects proinﬂammatory
cytokine responses to WWH- (IL-6, IL-8, and IL-23p19) and
SEA-speciﬁc IL-17A and was negatively loaded with Th2 cyto-
kines. Principle component 4 comprised SEA-speciﬁc TNF-α
and IL-13, both of which are associated with schistosome-as-
sociated immunopathology [34, 35].
Binary logistic regression analysis showed that participant
age, sex, and pretreatment infection intensity were not
signiﬁcant predictors of reinfection status, but high PC2 factor
scores (reﬂecting a combination of SEA-speciﬁc proinﬂamma-
tory [IL-6, IL-12p70, IL-21, and IL-23p19] and WWH-speciﬁc
Th2- (IL-5) and Th17-associated [IL-21] responses) were sig-
niﬁcantly associated with a lower risk of reinfection (Table 4).
None of the other post-treatment cytokine proﬁles were signif-
icant predictors of reinfection status (Table 4).
DISCUSSION
Praziquantel treatment is known to affect levels of individual
schistosome-speciﬁc immune responses and may do so di-
rectly by killing parasites and exposing their antigens to
immune recognition [36, 37] and/or indirectly by removing
immunosuppressive mechanisms mediated by live parasites
[11]. The current study shows that the effects of treatment on
schistosome-speciﬁc cytokine responses are dependent both
on parasite life-cycle stage and the cellular phenotype with
which they are associated. In particular, cercariae- and egg-
speciﬁc, but not adult worm–speciﬁc, cytokine responses
become polarized toward a more proinﬂammatory phenotype
after treatment than that observed prior to treatment. Interest-
ingly, participants who became reinfected within 18 months
Table 1. Schistosome-Speciﬁc Cytokine Responses Differ 6 Weeks After Treatment Relative to Pretreatment Levels
Phenotype Cytokine
Antigen
CAP WWH SEA
F Valuea P Value F Valuea P Value F Valuea P Value
Innate inflammatory TNF-α 3.70 0.07 6.18 0.02 75.24b <0.001b
IL-6 0.82 0.38 7.78 0.01 208.47b <0.001b
IL-8 64.92b <0.001b 2.38 0.13 90.49b <0.001b
Th1 IFN-γ 3.53 0.07 0.95 0.33 28.70b <0.001b
IL-2 4.32 0.05 0.01 0.93 4.79 0.03
IL-12p70 2.29 0.15 2.77 0.10 94.52b <0.001b
Th2 IL-4 0.76 0.39 2.70 0.10 1.34 0.25
IL-5 3.28 0.08 3.66 0.06 1.19 0.28
IL-13 7.41 0.01 0.17 0.68 1.91 0.17
Regulatory IL-10 9.09 0.01 3.45 0.07 1.38 0.24
Th17 IL-17A 0.07 0.79 1.04 0.31 0.26 0.61
IL-21 4.31 0.05 7.32 0.01 8.88b <0.001b
IL-23 5.01 0.04 1.34 0.25 190.15b <0.001b
Results of repeated measures analysis of variance comparing mean concentrations (square root(x + 1) transformed) of cytokines present in whole blood cultures
stimulated with cercariae (CAP), adult worm (WWH), and egg (SEA) antigens before treatment with those elicited 6 weeks after a single 40 mg/kg body weight
dose of praziquantel (CAP, n = 21; WWH, SEA, and unstimulated, n = 72). Significant differences (P < .05) are highlighted in bold.
Abbreviations: IFN-γ, interferon γ; IL-2, interleukin 2; IL-4, interleukin 4; IL-5, interleukin 5; IL-6, interleukin 6; IL-8, interleukin 8; IL-10, interleukin 10; IL-12p70;
interleukin 12p70; IL-13, interleukin 13; IL-17A, interleukin 17A; IL-21, interleukin 21; IL23, interleukin 23; TNF-α, tumor necrosis factor α.
a Error degrees of freedom: 1, 20 (CAP); 1, 71 (WWH and SEA).
b Differences that are significant after Bonferroni adjustment for multiple comparisons.
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of curative treatment had lower PC scores for a combination
of egg-speciﬁc proinﬂammatory and adult worm–speciﬁc IL-5
and IL-21 than their uninfected counterparts, suggesting that
the boost in proinﬂammatory responses to egg antigens
after treatment may promote resistance to reinfection. Impor-
tantly, quantiﬁcation of innate-, Th1-, Th2-, Treg- and Th17-
associated cytokine families allowed a more comprehensive
analysis of how treatment affects schistosome-speciﬁc cytokine
proﬁles than those described in previous studies. Use of a
multivariate statistical approach also facilitated meaningful
interpretation of highly complex responses, which are known
to interact and cross-regulate one another during helminth in-
fections [18, 19].
As initially hypothesized, levels of Th17-associated cyto-
kines (IL-21 and IL-23) changed markedly 6 weeks post-treat-
ment; however, the 2 cytokines had distinct antigen-speciﬁc
dynamics. Soluble egg antigen–speciﬁc IL-21 and IL-23 in-
creased in the context of a range of other proinﬂammatory
cytokines, cercariae-speciﬁc IL-21 was unchanged, cercariae-
speciﬁc IL-23 declined, and adult worm-induced IL-21, but
not IL-23, increased post-treatment. Interestingly, despite
being present at detectable levels in response to all antigens,
Figure 2. Cytokine proﬁles elicited by Schistosoma haematobium cercariae (CAP) (A), adult worm (WWH) (B), and egg (SEA) (C) antigens and spontaneous
cytokine production (D) differed 6 weeks post-treatment relative to pretreatment responses. Nonmetric multidimensional scaling ordination plots of partici-
pants’ combined cytokine responses (interferon γ [IFN-γ], tumor necrosis factor α [TNF-α], interleukin 2 [IL-2], interleukin 4 [IL-4], interleukin 5 [IL-5], interleu-
kin 6 [IL-6], interleukin 8 [IL-8], interleukin 10 [IL-10], interleukin 12p70 [IL-12p70], interleukin 13 [IL-13], interleukin 17A [IL-17A], interleukin 21 [IL-21], and
interleukin 23 [IL-23]) before (gray triangles) and 6 weeks after treatment (black triangles) plotted according to 2-dimensional spatial axes (CAP, n = 21;
WWH, SEA, and unstimulated, n = 72). The proportion of variance in participant cytokine responses attributable to each axis (Pearson’s r2) is shown. Axes
are labelled according to the cytokines with which they are most strongly correlated (correlation coefﬁcients for these associations provided in Supplementary
Table 1). Axis 2 of the WWH-speciﬁc cytokine ordination plot was not strongly associated with any of the pre- or post-treatment cytokine responses assayed.
Mean within-group differences reﬂect the total variation between participant cytokine responses before (white diamond) and after (black diamond) treatment.
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IL-17A levels did not differ post-treatment, suggesting that
IL-21 and IL-23 may have IL-17A– (or indeed Th17-) inde-
pendent roles despite their shared association with the Th17
lineage. For example, murine IL-21 has also been implicated
in Th2 function and alternative activation of macrophages
[38]. Furthermore, murine dendritic, cell-derived, schisto-
some-speciﬁc IL-23 promotes T cell IL-17 in vitro, and
heightened IL-23 levels may also elicit tissue-derived proin-
ﬂammatory cytokines in vivo [23]. Further studies are
required to ascertain the cellular sources and functions of
IL-17, IL-21, and IL-23 in human schistosomiasis.
Distinct post-treatment responses to schistosome life-cycle
stages suggest that the exposure of stage-speciﬁc antigens
differs following treatment and is evident despite the overlap
in somatic antigens [39]. For example, the low cytokine re-
sponsiveness to WWH post-treatment may be due to rapid
removal of adult worms from the circulation [40], whereas
ongoing contact with cercariae-infected water [41] and pro-
longed excretion of eggs from host tissues [5] may have main-
tained exposure to these life-cycle stages during the 6 weeks
following treatment. Thus, our results do not preclude the
possibility that cellular immune responses to adult worms are
“boosted” at earlier post-treatment timepoints, as observed in
S. mansoni studies [17, 42], but indicate that these effects
decline within 6 weeks without repeated treatment.
Egg- and cercariae-speciﬁc proinﬂammatory responses may
also increase post-treatment due to disruption of immunosup-
pression mediated by live parasites during infection [43]. This
hypothesis is supported by observations that circulating Treg
numbers decrease postclearance of S. mansoni [11], suggesting
that infection elevates peripheral immunoregulation. However,
observed changes in SEA-speciﬁc cytokines were not due to
changes in egg-speciﬁc IL-10, which was unaffected by treat-
ment. Thus, treatment-dependent elevation of SEA-speciﬁc
proinﬂammatory cytokines may reﬂect changes in alternative
mechanisms (eg, Tregs [35, 44]) regulating SEA-speciﬁc re-
sponses during infection. Consistent with the latter hypothe-
sis, levels of spontaneous IL-10 were lower post-treatment
than pretreatment, and we have previously shown that serolog-
ical responses to non-parasite antigens increase post-treatment
in the same population [14]. Regulation of egg-speciﬁc re-
sponses prior to treatment may be particularly important due
to their immunopathological potential. For example, IL-13
and TNF-α, which are associated with egg-induced immuno-
pathology [34, 35] and Th1 cytokines (IFN-γ and IL-12p70),
which tend to be lower in chronically infected than uninfected
humans [45, 46], were signiﬁcantly higher 6 weeks post-treat-
ment. The elevated IL-21 and IL-23 responses to SEA post-
treatment are also consistent with a “rebound” in potentially
pathological responses after removal of infection because
Th17-associated responses exacerbate egg-induced granulomas
in experimental schistosomiasis [21, 22].
This study also tested the hypothesis that post-treatment
cytokine proﬁles inﬂuence the acquisition of new schistosome
infections. Whereas some human helminth studies have
focused on how pretreatment immune responses relate to re-
infection [12, 47], we focused on post-treatment responses
because reinfection occurs in the context of this altered
immune environment. High post-treatment PC2 scores (com-
prising SEA-speciﬁc proinﬂammatory cytokines and WWH-
speciﬁc IL-5 and IL-21) were associated with a reduced risk of
reinfection within 18 months of treatment, consistent with an
immune-mediated component to protective immunity rather
than age-related changes in water contacts or immune physi-
ology alone [48]. Only 18 participants were reinfected within
18 months of treatment, and thus reinfection analysis may
have lacked statistical power to detect other signiﬁcant associa-
tions. Nonetheless, our data provide the ﬁrst evidence that
Th17-associated IL-23 and IL-21 may contribute to protection
from schistosome infection in addition to their putative im-
munopathological effects [21], and thus our data advocate
further study of these cytokines in human schistosomiasis.
The association between adult worm-speciﬁc Th2 cytokines
and resistance to reinfection has been noted previously [9, 13]
but never assessed in the context of innate inﬂammatory, Th1,
Th17, and regulatory cytokines which can cross-regulate Th2
responses [19].
Because eggs are only produced after an infection has
already been established, immune responses targeting egg an-
tigens alone are unlikely to directly reduce reinfection. What
seems more likely is that post-treatment, egg-speciﬁc, proin-
ﬂammatory cytokine levels correspond to responses that limit
Table 2. Demographic and Schistosoma haematobium Infection
Characteristics of the Study Cohort 18 Months After Praziquantel
Treatment
Reinfection status
Characteristics Uninfected Reinfecteda
No. 54 18
Mean age (SEM) 9.2 (0.37) 9.3 (0.53)
Males, females 27, 27 13, 5
Mean pretreatment infection intensitya 28.6 (11.0) 35.6 (21.9)
Pretreatment infection rangeb 0–481 0–395
Pretreatment infection prevalence 57.4% 61.1%
Mean post-treatment infection intensityb
(SEM)
0 10.2 (4.5)
Post-treatment infection rangeb (SEM) 0 0–65
Abbreviation: SEM, standard error of the mean.
a Reinfection classified as presence of ≥1 S. haematobium egg in ≥1 urine
sample between 6 months and 18 months post-treatment.
b Infection intensity quantified as mean S. haematobium egg counts/10 mL urine.
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de novo invasion by cercariae or the ﬁtness and/or fecundity
of adult worms. For example, SEA contains a range of anti-
gens that cross-react with CAP, WWH, and schistosomules
[39], and therefore increased reactivity to egg-stage parasites
may also promote anti-larval and anti–adult worm responses
[49]. Consistent with our observations, individuals with low
peripheral blood mononuclear cell proliferative responses to
S. mansoni SEA (and CAP) were more likely to be reinfected
independent of age, sex, and pretreatment infection intensity
in an Egyptian cohort [50]. Interestingly, we show that CAP-
speciﬁc IL-8, IL-10, and IL-13 increase post-treatment;
however, the limited number of cases for which CAP stimula-
tion was conducted meant their relationship with reinfection
rates could not be assessed.
This study provides the most comprehensive analysis of
schistosome-speciﬁc cytokine responses in human schisto-
somiasis to date and the ﬁrst description of human
Th17 cytokine responses to schistosome antigens. Our results
demonstrate that a single dose of PZQ markedly alters the
polarization of schistosome-speciﬁc cytokine responses and
that these changes, particularly in response to egg-stage para-
sites, may contribute to the development of resistance to
reinfection.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases
online (http://jid.oxfordjournals.org/). Supplementary materials consist of
Table 3. Adult Worm and Egg-Speciﬁc Cytokine Proﬁles 6 Weeks After Treatment
Phenotype Cytokine Antigen
Principal Component
1 2 3 4
Th2/Regulatory
SEA Proinflammatory/
WWH Th2/Th17 WWH Proinflammatory SEA Proinflammatory/Th2
Innate inflammatory TNF-α SEA −0.5 0.3 0.1 0.5
WWH 0.3 0.4 0.1 −0.1
IL-6 SEA −0.7 0.5 0.1 0.2
WWH −0.3 0.1 0.7 −0.2
IL-8 SEA −0.1 0.1 0.0 0.3
WWH −0.2 0.1 0.7 −0.4
Th1 IFN-γ SEA −0.4 0.4 0.1 0.4
WWH 0.1 0.1 0.1 0.1
IL-2 SEA 0.4 0.1 0.1 0.2
WWH 0.6 0.1 0.2 0.2
IL-12p70 SEA −0.4 0.5 0.1 0.4
WWH 0.2 0.1 0.0 0.0
Th2 IL-4 SEA 0.2 0.4 −0.5 −0.2
WWH 0.1 0.4 −0.5 −0.3
IL-5 SEA 0.1 0.4 −0.5 −0.3
WWH −0.1 0.6 −0.4 0.0
IL-13 SEA 0.6 0.0 0.1 0.5
WWH 0.7 0.1 0.1 0.3
Regulatory IL-10 SEA 0.7 0.1 0.2 0.4
WWH 0.5 0.1 0.3 0.4
Th17 IL-17A SEA 0.2 0.4 0.5 −0.5
WWH 0.3 0.4 0.3 −0.5
IL-21 SEA 0.2 0.6 −0.1 0.0
WWH 0.4 0.7 −0.1 −0.1
IL-23 SEA −0.5 0.5 0.1 0.4
WWH 0.0 0.0 0.5 −0.2
% Total variance 15.6 12.3 15.4 12.5
Antigen-specific cytokine factor loadings for principal components (PCs) 1–4 extracted by factor analysis of all Schistosoma haematobium whole worm
homogenate (WWH)– and soluble egg antigen (SEA)–specific cytokine responses 6 weeks after praziquantel treatment (n = 72). Cytokines with factor loadings
≥0.5 or≤−0.5 for an extracted PC are highlighted in bold. The cellular immune phenotype with which the cytokines are associated is given for each PC. The
percentage of total variance in cytokine responses accounted for by each PC is given at the bottom of the relevant column.
Abbreviations: IFN-γ, interferon γ; IL-2, interleukin 2; IL-4, interleukin 4; IL-5, interleukin 5; IL-6, interleukin 6; IL-8, interleukin 8; IL-10, interleukin 10; IL-12p70;
interleukin 12p70; IL-13, interleukin 13; IL-17A, interleukin 17A; IL-21, interleukin 21; IL23, interleukin 23; TNF- α, tumor necrosis factor α.
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data provided by the author that are published to beneﬁt the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages
regarding errors should be addressed to the author.
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